Updated Feb. 19, 2013 at 1:25 p.m.

Premium Lock GSK, partner Theravance target December for heart disease drug decision

Published: 2013-02-19 13:20:00
Updated: 2013-02-19 13:25:26


GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) said Tuesday that the New Drug Application (NDA) for a  investigational combination medicine to treat patients with chronic obstructive pulmonary disease (COPD) has been accepted by the U.S. Food and Drug Administration....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2017 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders